-
Farley Parks posted an update 6 months, 4 weeks ago
The influence of the flexural modulus of prefabricated posts on the fracture resistance of endodontically treated teeth is unclear.
The purpose of this invitro study was to evaluate the influence of post material and post diameter on the fracture resistance of endodontically treated mandibular premolars. In addition, the influence of tooth substance loss was evaluated by comparing 1 with 2 residual dentinal walls.
Sixty-four extracted mandibular first premolars were endodontically treated and divided into 8 test groups (n=8) based on the number of residual walls (1 or 2), post material (glass fiber or titanium) and post diameter (International Standards Organization 70 or ISO 90). After luting the posts, the specimens received a composite resin core and a crownpreparation with a 2-mm ferrule. Cast Co-Cr crowns were cemented with glass ionomer cement. After 1 200 000 mastication cycles with a load of 49 N and simultaneous thermocycling (5 °C-55 °C), specimens were quasistatically loaded at 30 degrees to the longitudinal axis of the tooth until fracture. Fracture loads were analyzed by using 3-way ANOVA (α=.05). ZM 447439 Fracture modes were examined with a stereomicroscope at×25 magnification and recorded.
Fracture loads ranged from 954 ±35 N (1 residual wall-glass fiber-ISO 70) to 1286 ±202 N (1 residual wall-glass fiber-ISO 90). Titanium posts showed a statistically significant higher fracture resistance than glass fiber posts. A statistically significant increase in fracture resistance was also observed with increasing post diameter. However, no significant difference was found with respect to the number of residual walls (P>.05).
Teeth restored with titanium posts exhibited higher fracture resistance than teeth restored with glass fiber posts, especially when smaller diameter posts were used.
Teeth restored with titanium posts exhibited higher fracture resistance than teeth restored with glass fiber posts, especially when smaller diameter posts were used.Solitary fibrous tumour (SFT) is well-described in the urinary tract, but malignant examples are rare. We studied our experience with high grade malignant SFT of the prostate to address the degree of histological and immunophenotypical overlap with sarcomatoid carcinoma and prostatic stromal sarcoma. Four cases were identified from the surgical pathology consultation archives. All available H&E stained sections were reviewed. Immunostains for STAT6, CAM5.2, NKX3.1, PAX-8, GATA3, high molecular weight cytokeratin (34BE12), p40, and p63 were performed on available material. Each case was evaluated by three separate SFT prognostic risk models based on clinicopathological features, and for features of ‘dedifferentiated SFT’. The patient’s ages were 49, 55, 69, and 73 years. Three presented with symptoms of benign prostatic hyperplasia and one with haematuria. Tumour sizes were 5, 9, 13, and 13 cm. Mitotic rate ranged from 6 to 20 mitoses per 10 high power fields, and two cases showed abrupt transition from conventional SFT to areas with marked nuclear pleomorphism/anaplasia (i.e., ‘de-differentiation’). Immunophenotypically, all four cases had strong and diffuse nuclear reactivity for STAT6. For other markers, three of three had both focal PR and GATA3 nuclear expression (up to 30% of cells). One case with ‘dedifferentiated’ features showed expression of multiple epithelial markers, including EMA (focal), high molecular weight cytokeratin (focal), p63, and p40. In summary, malignant SFT may rarely occur in the prostate and may closely mimic sarcomatoid carcinoma or prostatic stromal sarcoma, both histologically and immunophenotypically. Consideration of the diagnostic possibility of malignant SFT, recognition of unexpected GATA3 and PR expression, and utilisation of monoclonal STAT6 immunohistochemistry facilitate appropriate diagnosis at this unusual anatomical site.Embedding physiological markers into treatment algorithms has helped trauma teams rationalise interventions safely and signifies a departure from the dichotomy of damage control orthopaedics (DCO) and early total care (ETC) to early appropriate care (EAC). This has been shown to reduce length of stay and cost to treating centres. This article seeks to provide a clear summary of current concepts for managing orthopaedic injuries in the multiply injured patient.
Cardiovascular disease is commonly seen in patients with end-stage renal disease (ESRD) and is a major cause of graft failure and death in patients undergoing kidney transplant.
The retrospective study included 77 patients with ESRD who underwent combined coronary artery bypass grafting (CABG) and kidney transplant between May 2010 and September2017.
The patients included 65 (84.4%) men and 12 (15.6%) women. Diabetes mellitus (DM) and hypertension (HT) were present in 71.4% and 90.9% of the patients, respectively. Mean postoperative intensive care unit (ICU) stay was 3.4 ± 1.6 days, mean time to extubation was 12.1 ± 3.7 hours, and mean hospital stay was 11.6 ± 3.5 days. In the small group with graft rejection, EF was 41.1 ± 12.3. Two patients underwent second kidney transplant, and 1 patient underwent a third kidney transplant. Mean amount of red blood cells (RBC) and fresh-frozen plasma (FFP) transfusion was 2.6 ± 0.7 and 2.1 ± 0.7 units, respectively.
The study showed that CABG and kidney transplant can be performed in a combined approach in the same session and that this combined approach is likely to have a more favorable effect on mortality and morbidity compared to the administration of these 2 surgeries in separate sessions.
The study showed that CABG and kidney transplant can be performed in a combined approach in the same session and that this combined approach is likely to have a more favorable effect on mortality and morbidity compared to the administration of these 2 surgeries in separate sessions.The avenue of effective migraine therapies blocking calcitonin gene-related peptide (CGRP) transmission is the successful outcome of 35 years of translational research. Developed after short-acting, the small antagonists of the CGRP receptor (the “gepants”), the monoclonal antibodies blocking CGRP or its receptor (CGRP/rec mAbs) have changed the paradigm in migraine treatment. Contrary to the classical acute medications like triptans or nonsteroidal anti-inflammatory drugs (NSAIDs) with a transient effect, they act for long durations exclusively in the peripheral portion of the trigeminovascular system and can thus be assimilated to a durable attack treatment, unlike the classical preventives that chiefly act upstream on the central facets of migraine pathophysiology. Randomized controlled trials (RCT) of eptinezumab, erenumab, fremanezumab and galcanezumab have included collectively several thousands of patients, making them the most extensively studied class of preventive migraine treatments. Their results clearly indicate that CGRP/rec mAbs are significantly superior to placebo and have been comprehensively reviewed by Dodick .